西南国防医药
西南國防醫藥
서남국방의약
MEDICAL JOURNAL OF NATIONAL DEFENDING FORCES IN SOUTHWEST CHINA
2014年
6期
615-617
,共3页
丙种球蛋白%重症肺炎%患儿%免疫功能
丙種毬蛋白%重癥肺炎%患兒%免疫功能
병충구단백%중증폐염%환인%면역공능
immunoglobulin%severe pneumonia%children%immune function
目的：观察静脉注射丙种球蛋白（ IVIG）对重症肺炎患儿体液免疫及细胞免疫的影响。方法重症肺炎患儿68例作为观察对象，按照治疗方法分为IVIG组（n＝38）和对照组（n＝30）。其中IVIG组在常规综合治疗的基础上静脉滴注丙种球蛋白400 mg/（ kg·d），连续应用3 d。分别于治疗前、治疗后3、7、14 d检测患儿IgM、IgG、IgA水平，血清IL-6、TNF-α水平，CD3、CD4、CD8阳性细胞百分率及CD4/CD8比值。结果 IVIG组在治疗后3 d，IgM、IgG、IgA即较治疗前显著升高，尤其是IgG升高更为显著（P﹤0.01），而对照组较治疗前无显著变化（P﹥0.05），两组相比，IVIG组IgG、IgA显著高于对照组（ P﹤0.01）。IVIG组IL-6及TNF-α在治疗后3 d即较治疗前显著降低（ P﹤0.01），并且显著低于对照组（ P﹤0.01）；在治疗后7 d及14 d时仍较治疗前显著降低（ P﹤0.01）。CD3、CD4、CD8、CD4/CD8在IVIG组治疗后3 d起较治疗前即显著升高（ P﹤0.01），在治疗后7 d及14 d仍显著高于治疗前（P﹤0.01）；两组相比，在治疗后3 d，IVIG组均显著高于对照组（P﹤0.01）。结论 IVIG可促进重症肺炎患儿体液免疫和细胞免疫功能，有助于患儿度过重症肺炎危险期。
目的：觀察靜脈註射丙種毬蛋白（ IVIG）對重癥肺炎患兒體液免疫及細胞免疫的影響。方法重癥肺炎患兒68例作為觀察對象，按照治療方法分為IVIG組（n＝38）和對照組（n＝30）。其中IVIG組在常規綜閤治療的基礎上靜脈滴註丙種毬蛋白400 mg/（ kg·d），連續應用3 d。分彆于治療前、治療後3、7、14 d檢測患兒IgM、IgG、IgA水平，血清IL-6、TNF-α水平，CD3、CD4、CD8暘性細胞百分率及CD4/CD8比值。結果 IVIG組在治療後3 d，IgM、IgG、IgA即較治療前顯著升高，尤其是IgG升高更為顯著（P﹤0.01），而對照組較治療前無顯著變化（P﹥0.05），兩組相比，IVIG組IgG、IgA顯著高于對照組（ P﹤0.01）。IVIG組IL-6及TNF-α在治療後3 d即較治療前顯著降低（ P﹤0.01），併且顯著低于對照組（ P﹤0.01）；在治療後7 d及14 d時仍較治療前顯著降低（ P﹤0.01）。CD3、CD4、CD8、CD4/CD8在IVIG組治療後3 d起較治療前即顯著升高（ P﹤0.01），在治療後7 d及14 d仍顯著高于治療前（P﹤0.01）；兩組相比，在治療後3 d，IVIG組均顯著高于對照組（P﹤0.01）。結論 IVIG可促進重癥肺炎患兒體液免疫和細胞免疫功能，有助于患兒度過重癥肺炎危險期。
목적：관찰정맥주사병충구단백（ IVIG）대중증폐염환인체액면역급세포면역적영향。방법중증폐염환인68례작위관찰대상，안조치료방법분위IVIG조（n＝38）화대조조（n＝30）。기중IVIG조재상규종합치료적기출상정맥적주병충구단백400 mg/（ kg·d），련속응용3 d。분별우치료전、치료후3、7、14 d검측환인IgM、IgG、IgA수평，혈청IL-6、TNF-α수평，CD3、CD4、CD8양성세포백분솔급CD4/CD8비치。결과 IVIG조재치료후3 d，IgM、IgG、IgA즉교치료전현저승고，우기시IgG승고경위현저（P﹤0.01），이대조조교치료전무현저변화（P﹥0.05），량조상비，IVIG조IgG、IgA현저고우대조조（ P﹤0.01）。IVIG조IL-6급TNF-α재치료후3 d즉교치료전현저강저（ P﹤0.01），병차현저저우대조조（ P﹤0.01）；재치료후7 d급14 d시잉교치료전현저강저（ P﹤0.01）。CD3、CD4、CD8、CD4/CD8재IVIG조치료후3 d기교치료전즉현저승고（ P﹤0.01），재치료후7 d급14 d잉현저고우치료전（P﹤0.01）；량조상비，재치료후3 d，IVIG조균현저고우대조조（P﹤0.01）。결론 IVIG가촉진중증폐염환인체액면역화세포면역공능，유조우환인도과중증폐염위험기。
Objective To observe the effect of intravenous immunoglobulin( IVIG ) on humoral and cellular immunity of children with severe pneumonia. Methods 68 children with severe pneumonia were divided into 2 groups:IVIG group( n=38 )and control group(n=30);routine treatment was applied to children in both group,while intravenous immunoglobulin,400 mg/(kg·d), was added to children in IVIG group for 3 days;the serum level of IgM,IgG,IgA,IL-6 and TNF-α,the positive percentage of CD3, CD4,CD8 cells and the ratio of CD4/CD8 were detected before treatment and at the time point of 3,7 and 14 days after treatment, respectively. Results 3 days after treatment,the levels of IgM,IgG,IgA of the children in IVIG group went up much higher than those before treatment,especially the level of IgG increased most obviously(P﹤0. 01),while the levels of children in control group were of no obvious changes(P﹥0. 05);the contrast study between the 2 groups showed that the levels of IgG and IgA in IVIG groups were much higher than those in control group(P﹤0. 01);3,7 and 14 days after treatment,the levels of IL-6 and TNF-α of the children in IVIG group were much lower than those before treatment(P﹤0. 01),and significant lower than those in control group;3,7 and 14 days after treatment,the positive percentage of CD3,CD4,CD8 cells and the ratio of CD4/CD8 of the children in IVIG groups increased much higher than those before treatment(P﹤0. 01);the contrast study between the 2 groups 3 days after treatment showed that the effect in IVIG group was much superior to that in control group(P﹤0. 01). Conclusions IVIG can promote the humoral and cellular immunity of children with severe pneumonia and can help the children to get through the risky period.
